microarray-based assay Search Results


microarray-based comparative genomic hybridization  (Kohlhammer GmbH)
90
Kohlhammer GmbH microarray-based comparative genomic hybridization
Microarray Based Comparative Genomic Hybridization, supplied by Kohlhammer GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm22739938-183-24-4?v=Kohlhammer+GmbH
Average 90 stars, based on 1 article reviews
microarray-based comparative genomic hybridization - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
targetprint her2 gene expression  (Agendia BV)
90
Agendia BV targetprint her2 gene expression
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Targetprint Her2 Gene Expression, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pmc05259561-162-8-14?v=Agendia+BV
Average 90 stars, based on 1 article reviews
targetprint her2 gene expression - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
protein chip  (GenTel BioSurfaces)
90
GenTel BioSurfaces protein chip
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Protein Chip, supplied by GenTel BioSurfaces, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/10__1038_slash_nbt0208___246-2-9-12?v=GenTel+BioSurfaces
Average 90 stars, based on 1 article reviews
protein chip - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human interferon and receptor rt 2 profiler pcr array  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation human interferon and receptor rt 2 profiler pcr array
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Human Interferon And Receptor Rt 2 Profiler Pcr Array, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pmc03233139-55-29-38?v=SuperArray+Bioscience+Corporation
Average 90 stars, based on 1 article reviews
human interferon and receptor rt 2 profiler pcr array - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
pcr-product-based dna microarrays  (Federation of European Neuroscience Societies)
90
Federation of European Neuroscience Societies pcr-product-based dna microarrays
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Pcr Product Based Dna Microarrays, supplied by Federation of European Neuroscience Societies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm17096662-31-15-25?v=Federation+of+European+Neuroscience+Societies
Average 90 stars, based on 1 article reviews
pcr-product-based dna microarrays - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
extended prototype protein microarray  (RayBiotech inc)
90
RayBiotech inc extended prototype protein microarray
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Extended Prototype Protein Microarray, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pmc03432681-74-2-8?v=RayBiotech+inc
Average 90 stars, based on 1 article reviews
extended prototype protein microarray - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
oligo-based microarray for mouse general pathway  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation oligo-based microarray for mouse general pathway
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Oligo Based Microarray For Mouse General Pathway, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm18036154-72-22-27?v=SuperArray+Bioscience+Corporation
Average 90 stars, based on 1 article reviews
oligo-based microarray for mouse general pathway - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
microarray-based ribonomics approach  (Ribonomics Inc)
90
Ribonomics Inc microarray-based ribonomics approach
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Microarray Based Ribonomics Approach, supplied by Ribonomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pmc02040218-107-4-5?v=Ribonomics+Inc
Average 90 stars, based on 1 article reviews
microarray-based ribonomics approach - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
microarray-based comparative whole-genome resequencing cgr  (NimbleGen Systems GmbH)
90
NimbleGen Systems GmbH microarray-based comparative whole-genome resequencing cgr
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Microarray Based Comparative Whole Genome Resequencing Cgr, supplied by NimbleGen Systems GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm20143945-224-2-9?v=NimbleGen+Systems+GmbH
Average 90 stars, based on 1 article reviews
microarray-based comparative whole-genome resequencing cgr - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
microarray-based dtc  (Navigenics Inc)
90
Navigenics Inc microarray-based dtc
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Microarray Based Dtc, supplied by Navigenics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm25676199-24-11-0?v=Navigenics+Inc
Average 90 stars, based on 1 article reviews
microarray-based dtc - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
symphony suite of microarray-based assays  (Agendia BV)
90
Agendia BV symphony suite of microarray-based assays
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Symphony Suite Of Microarray Based Assays, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm28333918-49-21-11?v=Agendia+BV
Average 90 stars, based on 1 article reviews
symphony suite of microarray-based assays - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
microarray-based whole-genome surveys  (Schmid GmbH)
90
Schmid GmbH microarray-based whole-genome surveys
Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if <t>HER2+)</t> cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.
Microarray Based Whole Genome Surveys, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+assay/pm18694447-33-2-28?v=Schmid+GmbH
Average 90 stars, based on 1 article reviews
microarray-based whole-genome surveys - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if HER2+) cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Patients are screened for I-SPY 2 eligibility. Eligible patients are adaptively randomized to 12 weekly paclitaxel (and trastuzumab if HER2+) cycles (control) or in combination with one of several experimental agents followed by doxorubicin/cyclophosphamide (AC) × 4, with serial biomarkers (biopsies, blood draw and MRI scans) assessed over the course of their therapy. Only patients with HER2− disease were randomized to the veliparib/carboplatin arm.

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques:

Only patients with HER2-negative disease were eligible for randomization to the VC arm. Patients were categorized as received allocated invention if they received at least one dose of experimental (or control) therapy.

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Only patients with HER2-negative disease were eligible for randomization to the VC arm. Patients were categorized as received allocated invention if they received at least one dose of experimental (or control) therapy.

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques:

Estimated pCR Rate for the signatures evaluated for V/C vs. concurrent HER2-negative control.

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Estimated pCR Rate for the signatures evaluated for V/C vs. concurrent HER2-negative control.

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques: Negative Control

Final predictive probabilities

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Final predictive probabilities

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques:

Selected Toxicities

Journal: The New England journal of medicine

Article Title: Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

doi: 10.1056/NEJMoa1513749

Figure Lengend Snippet: Selected Toxicities

Article Snippet: Biomarker assessments include the Agendia 70-gene MammaPrint and TargetPrint HER2 gene expression using the Agendia 44K full genome microarray and reverse phase phosphoprotein array.

Techniques: